Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 21:12:1756284819847034.
doi: 10.1177/1756284819847034. eCollection 2019.

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

María Chaparro  1 , Manuel Barreiro-de Acosta  2 , José Manuel Benítez  3 , José Luis Cabriada  4 , María José Casanova  5 , Daniel Ceballos  6 , María Esteve  7 , Hipólito Fernández  8 , Daniel Ginard  9 , Fernando Gomollón  10 , Rufo Lorente  11 , Pilar Nos  12 , Sabino Riestra  13 , Montserrat Rivero  14 , Pilar Robledo  15 , Cristina Rodríguez  16 , Beatriz Sicilia  17 , Emilio Torrella  18 , Ana Garre  5 , Esther García-Esquinas  19 , Fernando Rodríguez-Artalejo  19 , Javier P Gisbert  5 ; EpidemIBD study group of GETECCU
Collaborators, Affiliations

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

María Chaparro et al. Therap Adv Gastroenterol. .

Abstract

Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes.

Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn's disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded.

Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up.

Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.

Keywords: Crohn’s disease; epidemiology; incidence; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: M. Chaparro has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, and Tillotts Pharma. M.J. Casanova has received education funding from Pfizer, Janssen, MSD, Abbvie, Ferring, Faes Farma, and Shire Pharmaceuticals. F. Gomollón has received honoraria for conference attendance from Janssen, Abbvie, Takeda and MSD, financial support for travel and registration to attend international conferences from Abbvie, Takeda and Janssen, and his research group has received financial grants from MSD, Abbvie and Tillots. J.L. Cabriada has served as consultant for, or received research funding from, MSD, Pfizer, Janssen, Takeda and Otsuka Pharma. M. Barreiro-de Acosta has served as a speaker, a consultant and advisory board member for, or has received research funding from, MSD, Abbvie, Janssen, Pfizer, Kern Pharma, Biogen, Takeda, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Gebro Pharma, Otsuka Pharma-ceutical and Vifor Pharma. S. Riestra has received honoraria for conference attendance from Janssen, Abbvie, Takeda and MSD, financial support for travel and registration to attend conferences from Abbvie, MSD and Janssen, and his research group has received financial grants from MSD, Abbvie and Takeda. M. Rivero has served as a speaker, a consultant and advisory board member for MSD, Abbvie and Janssen. M. Esteve acts as a consultant, assessor or scientific advisor for Abbott, MSD, Tillotts Pharma, Pfizer and Takeda and received research grants for MSD and Tillotts Pharma. J.P. Gisbert has served as a speaker, a consultant and advisory board member for, or has received research funding from, MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Vifor Pharma.

Figures

Figure 1.
Figure 1.
Study sites.
Figure 2.
Figure 2.
Program of clinic visits over the course of the study.
See this image and copyright information in PMC

References

    1. Dulai PS, Singh S, Ohno-Machado L, et al. Population health management for inflammatory bowel disease. Gastroenterology 2018; 154: 37–45. - PubMed
    1. Duricova D, Burisch J, Jess T, et al. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis 2014; 8: 1351–1361. - PubMed
    1. Kim YS, Jung SA, Lee KM, et al. Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. Intest Res 2017; 15: 338–344. - PMC - PubMed
    1. Lonnfors S, Vermeire S, Greco M, et al. IBD and health-related quality of life – discovering the true impact. J Crohns Colitis 2014; 8: 1281–1286. - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.e42; quiz e30. - PubMed